IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

Compare

608 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IDYA Analyst Ratings

Strong Buy

15 Buy

2 Hold

0 Sell

Based on 17 analysts giving stock ratings to

IDEAYA

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IDYA Stock 12 Month Forecast

Average Price Target

$45.14

▲(67.68% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $45.14 with a high forecast of $64.00 and a low forecast of $25.00. The average price target represents a 67.68% change from the last price of $26.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","26":"$26","39":"$39","52":"$52","65":"$65"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$64.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,26,39,52,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,30.178461538461537,32.996923076923075,35.815384615384616,38.63384615384615,41.45230769230769,44.27076923076923,47.08923076923077,49.90769230769231,52.72615384615385,55.54461538461538,58.363076923076925,61.181538461538466,{"y":64,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,28.72769230769231,30.095384615384614,31.463076923076922,32.83076923076923,34.19846153846154,35.566153846153846,36.933846153846154,38.30153846153846,39.669230769230765,41.036923076923074,42.40461538461538,43.77230769230769,{"y":45.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,27.178461538461537,26.996923076923075,26.815384615384616,26.633846153846154,26.45230769230769,26.27076923076923,26.08923076923077,25.907692307692308,25.726153846153846,25.544615384615383,25.363076923076925,25.181538461538462,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$64.00

Average Price Target$45.14

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

10/08/25

IDEAYA Biosciences: Promising Outlook for Darovasertib in Uveal Melanoma Drives Buy Rating

Silvan Tuerkcan

Citizens JMP

$45

Buy

67.16%

Upside

Reiterated

10/07/25

Citizens JMP Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $45.00 price target on Ideaya Biosciences (NASDAQ: IDYA).

David Dai

UBS

$50

Buy

85.74%

Upside

Reiterated

09/23/25

UBS Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

Paul Jeng

Guggenheim

$50

Buy

85.74%

Upside

Initiated

09/17/25

Ideaya Biosciences initiated with a Buy at GuggenheimIdeaya Biosciences initiated with a Buy at Guggenheim

Charles Zhu

LifeSci Capital

$58

Buy

115.45%

Upside

Reiterated

09/12/25

IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating

Graig Suvannavejh

Mizuho Securities

$43→$44

Buy

63.45%

Upside

Reiterated

09/12/25

Mizuho Securities Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Andrew Berens

Leerink Partners

$27→$30

Hold

11.44%

Upside

Reiterated

09/10/25

Leerink Partners Keeps Their Hold Rating on IDEAYA Biosciences (IDYA)Leerink Partners analyst Andrew Berens raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $30.00 (from $27.00) while maintaining a Market Perform rating.

Eva Fortea Verdejo

Wells Fargo

$44

Buy

63.45%

Upside

Reiterated

09/09/25

Ideaya should be bought on yesterday's selloff, says Wells FargoIdeaya should be bought on yesterday's selloff, says Wells Fargo

Yigal Nochomovitz

Citi

$64

Buy

137.74%

Upside

Assigned

09/09/25

Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW) and IDEAYA Biosciences (NASDAQ: IDYA)

Justin Zelin

BTIG

$62

Buy

130.31%

Upside

Reiterated

09/09/25

Promising Pipeline and Competitive Edge: IDEAYA Biosciences Receives Buy Rating from Analyst

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

09/09/25

Cantor Fitzgerald Remains a Buy on IDEAYA Biosciences (IDYA)Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and {REMOVEPT} price target on Ideaya Biosciences (NASDAQ: IDYA).

Leonid Timashev

RBC Capital

$36→$38

Buy

41.16%

Upside

Reiterated

09/08/25

RBC Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

09/08/25

IDEAYA Biosciences (IDYA) Receives a Buy from TD Cowen

Robert Driscoll

Wedbush

$46

Buy

70.88%

Upside

Reiterated

09/08/25

Peter Lawson

Barclays

$40

Buy

48.59%

Upside

Reiterated

09/08/25

Barclays Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

10/08/25

IDEAYA Biosciences: Promising Outlook for Darovasertib in Uveal Melanoma Drives Buy Rating

Silvan Tuerkcan

Citizens JMP

$45

Buy

67.16%

Upside

Reiterated

10/07/25

David Dai

UBS

$50

Buy

85.74%

Upside

Reiterated

09/23/25

UBS Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

Paul Jeng

Guggenheim

$50

Buy

85.74%

Upside

Initiated

09/17/25

Ideaya Biosciences initiated with a Buy at GuggenheimIdeaya Biosciences initiated with a Buy at Guggenheim

Charles Zhu

LifeSci Capital

$58

Buy

115.45%

Upside

Reiterated

09/12/25

IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating

Graig Suvannavejh

Mizuho Securities

$43→$44

Buy

63.45%

Upside

Reiterated

09/12/25

Mizuho Securities Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Andrew Berens

Leerink Partners

$27→$30

Hold

11.44%

Upside

Reiterated

09/10/25

Eva Fortea Verdejo

Wells Fargo

$44

Buy

63.45%

Upside

Reiterated

09/09/25

Ideaya should be bought on yesterday's selloff, says Wells FargoIdeaya should be bought on yesterday's selloff, says Wells Fargo

Yigal Nochomovitz

Citi

$64

Buy

137.74%

Upside

Assigned

09/09/25

Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW) and IDEAYA Biosciences (NASDAQ: IDYA)

Justin Zelin

BTIG

$62

Buy

130.31%

Upside

Reiterated

09/09/25

Promising Pipeline and Competitive Edge: IDEAYA Biosciences Receives Buy Rating from Analyst

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

09/09/25

Cantor Fitzgerald Remains a Buy on IDEAYA Biosciences (IDYA)Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and {REMOVEPT} price target on Ideaya Biosciences (NASDAQ: IDYA).

Leonid Timashev

RBC Capital

$36→$38

Buy

41.16%

Upside

Reiterated

09/08/25

RBC Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

09/08/25

IDEAYA Biosciences (IDYA) Receives a Buy from TD Cowen

Robert Driscoll

Wedbush

$46

Buy

70.88%

Upside

Reiterated

09/08/25

Peter Lawson

Barclays

$40

Buy

48.59%

Upside

Reiterated

09/08/25

Barclays Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering IDEAYA Biosciences

1 Month

xxx

Success Rate

10/16 ratings generated profit

Average Return

+5.16%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +5.16% per trade.

3 Months

xxx

Success Rate

13/20 ratings generated profit

Average Return

+9.29%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +9.29% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

15/20 ratings generated profit

Average Return

+37.82%

reiterated a buy rating 27 days ago

Copying Charles Zhu's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +37.82% per trade.

2 Years

xxx

Success Rate

14/20 ratings generated profit

Average Return

+37.38%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +37.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDYA Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IDYA has received 30 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. IDYA average Analyst price target in the past 3 months is 45.14.

Each month's total comprises the sum of three months' worth of ratings.

IDYA Financial Forecast

IDYA Earnings Forecast

Next quarter’s earnings estimate for IDYA is -$0.83 with a range of -$0.95 to -$0.63. The previous quarter’s EPS was -$0.88. IDYA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year IDYA has Preformed in-line its overall industry.

IDYA Sales Forecast

Next quarter’s sales forecast for IDYA is $6.38M with a range of $0.00 to $12.50M. The previous quarter’s sales results were $0.00. IDYA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year IDYA has Preformed in-line its overall industry.

IDYA Stock Forecast FAQ

What is IDYA’s average 12-month price target, according to analysts?

Based on analyst ratings, Ideaya Biosciences’s 12-month average price target is 45.14.

What is IDYA’s upside potential, based on the analysts’ average price target?

Ideaya Biosciences has 67.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IDYA a Buy, Sell or Hold?

Ideaya Biosciences has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.

What is Ideaya Biosciences’s price target?

The average price target for Ideaya Biosciences is 45.14. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $64.00 ,the lowest forecast is $25.00. The average price target represents 67.68% Increase from the current price of $26.92.

What do analysts say about Ideaya Biosciences?

Ideaya Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of IDYA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

IDYA Analyst Ratings

IDYA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering IDEAYA Biosciences

IDYA Analyst Recommendation Trends

IDYA Financial Forecast

IDYA Earnings Forecast

IDYA Sales Forecast

IDYA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts